海洋ω-3脂肪酸补充剂与安慰剂在降低健康美国成人干眼症发病率中的疗效:一项随机临床试验
该研究是VITAL试验的预设辅助研究,纳入23523名入组时无干眼症(DED)既往诊断且无严重干眼症状的美国成人,随机接受每日1 g海洋ω-3脂肪酸或安慰剂。在中位5.3年治疗随访期间,确诊DED发生率两组间无差异(2.0% vs 2.0%;HR 0.97;95%CI 0.81-1.16),复合终点亦无差异(8.9% vs 9.1%;HR 0.97;95%CI 0.89-1.06)。作者结论认为这些结果不支持推荐补充海洋ω-3脂肪酸以降低DED发病率。
要点
- 每日1 g海洋ω-3脂肪酸未降低确诊DED发病率(2.0% vs 2.0%;HR 0.97;95%CI 0.81-1.16)。
- 确诊DED或新发严重干眼症状复合终点两组无差异(8.9% vs 9.1%;HR 0.97;95%CI 0.89-1.06)。
- 作者结论认为结果不支持推荐补充海洋ω-3脂肪酸以降低DED发病率。
核心结论
- 在中位5.3年的治疗随访中,每日补充1 g海洋ω-3脂肪酸未降低确诊DED发病率或确诊DED与新发严重干眼症状的复合终点。
- 作者结论认为这些结果不支持推荐补充海洋ω-3脂肪酸以降低DED发病率。
研究设计与样本
- VITAL试验的预设辅助研究,为全国性随机双盲安慰剂对照2×2析因试验,评估维生素D和海洋ω-3脂肪酸在癌症和心血管疾病一级预防中的作用。
- 纳入23523名美国成人(男性50岁及以上、女性55岁及以上),入组时无DED既往诊断且无严重干眼症状。
- 入组时间为2011年11月至2014年3月,治疗和随访于2017年12月31日结束,数据分析时间为2020年1月至2021年8月。
- 干预为每日1 g海洋ω-3脂肪酸;主要终点为经病历复核确认的临床诊断新发DED,次要终点为所有确诊新发DED病例加所有新发严重干眼症状报告。
- 参与者平均(SD)年龄67.0(7.0)岁,11349名(48.3%)为女性。
主要发现
- 中位(范围)5.3(3.8-6.1)年治疗随访期间,23523名参与者中472名(2.0%)出现病历确认的DED诊断。
- 随机ω-3脂肪酸分组间确诊DED无差异:治疗组11757名中232名(2.0%)出现终点事件 vs 安慰剂组11766名中240名(2.0%)出现终点事件;HR 0.97;95%CI 0.81-1.16。
- 次要终点(确诊DED加新发严重干眼症状)两组亦无差异:治疗组1044名(8.9%)出现终点事件 vs 安慰剂组1074名(9.1%)出现终点事件;HR 0.97;95%CI 0.89-1.06。
- 队列中4610名(20.0%)自我认同为黑人,16481名(71.6%)自我认同为非西班牙裔白人,1927名(8.4%)为其他种族或族裔群体或拒绝回答(因人数少而合并,包括美国印第安人或阿拉斯加原住民、亚裔、西班牙裔或拉丁裔、夏威夷原住民或其他太平洋岛民)。
临床怎么用
- 作者结论认为这些结果不支持推荐补充海洋ω-3脂肪酸以降低DED发病率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Results of several small randomized clinical trials have suggested that supplements of marine ω-3 fatty acids may be beneficial in treating signs and symptoms of dry eye disease (DED). However, randomized clinical trial data to examine whether ω-3 fatty acid supplements can prevent DED are lacking. OBJECTIVE: To evaluate whether long-term daily supplementation with marine ω-3 fatty acids prevents the development of DED. DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified ancillary study of the Vitamin D and Omega-3 Trial (VITAL), a nationwide randomized double-blind placebo-controlled 2 × 2 factorial trial of vitamin D and marine ω-3 fatty acids in the primary prevention of cancer and cardiovascular disease. Participants in this ancillary study were 23 523 US adults (men 50 years and older and women 55 years and older) who at study entry were free of a previous diagnosis of DED and were not experiencing severe dry eye symptoms. Participants were enrolled from November 2011 to March 2014, and treatment and follow-up ended on December 31, 2017. Data were analyzed from January 2020 to August 2021. INTERVENTIONS: Marine ω-3 fatty acids, 1 g per day. MAIN OUTCOMES AND MEASURES: The primary end point was incident clinically diagnosed DED confirmed by review of the medical records. The secondary end point was a composite of all confirmed incident clinically diagnosed DED cases plus all incident reports of severe DED symptoms. RESULTS: The mean (SD) age of the 23 523 participants included in the analysis was 67.0 (7.0) years, and 11 349 participants (48.3%) were women. The cohort included 4610 participants (20.0%) who self-identified as Black, 16 481 (71.6%) who self-identified as non-Hispanic White, and 1927 (8.4%) of other racial or ethnic groups or who declined to respond, consolidated owing to small numbers, including American Indian or Alaska Native, Asian, Hispanic or Latino, and Native Hawaiian or Other Pacific Islander. During a median (range) 5.3 (3.8-6.1) years of treatment and follow-up, 472 of 23 523 participants (2.0%) experienced a medical record-confirmed diagnosis of DED. There was no difference in diagnosed DED by randomized ω-3 fatty acid assignment (232 of 11 757 participants [2.0%] with end points in the treated group vs 240 of 11 766 [2.0%] with end points in the placebo group; hazard ratio, 0.97; 95% CI, 0.81-1.16). Similarly, there was no difference between groups for the secondary end point of diagnosed DED plus incident severe DED symptoms (1044 participants [8.9%] with end points in the treated group vs 1074 [9.1%] with end points in the placebo group; hazard ratio, 0.97; 95% CI, 0.89-1.06). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, long-term supplementation with 1 g per day of marine ω-3 fatty acids for a median (range) of 5.3 (3.8-6.1) years did not reduce the incidence of diagnosed DED or a combined end point of diagnosed DED or incident severe DED symptoms. These results do not support recommending marine ω-3 fatty acid supplementation to reduce the incidence of DED. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01880463.
引用
- Christen WG, Cook NR, Manson JE, et al. Efficacy of Marine ω-3 Fatty Acid Supplementation vs Placebo in Reducing Incidence of Dry Eye Disease in Healthy US Adults: A Randomized Clinical Trial. JAMA Ophthalmol. 2022. PMID: 35679030. doi:10.1001/jamaophthalmol.2022.1818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。